Health Effects Assessment Summary (HEAST) for
Silver
CAS: 007440-22-4
| Summary of HEAST Information on-Line | ||||||
| Subchronic and Chronic Toxicity | ||||||
|
| Subchronic [RfD]: (see comment) |
5E-3 mg/kg/day | ||
| Uncertainty Factor: | 3 | ||
| Route: | IV | ||
| Target Organ / Critical Effect: | Skin / Argyria | ||
| Species | Effect Level | Dose | Experiment Length |
| Human | LOAEL | 0.014 mg/kg/day | 2-9 years |
| References | |||
| 1935 | Gaul L.E. and A.N. Staud. 1935. Clinical spectroscopy. Seventy cases of generalized argyria following organic and colloidal Silver medication. J Am Med Assoc. 104: 1387-1390. | ||
| 1934 | Blumberg H. and T.N. Carey. 1934. Argyremia: Detection of unsuspected and obscure argyria by the spectrographic demonstration of high blood Silver. J Am Med Assoc. 103: 1521-1524. | ||
| 1980 | East B.W., K. Boddy, E.D. Williams, D. Macintyre and A.L.C. McLay.1980. Silver retention, total body Silver and tissue Silver concentrations in argyria associated with exposure to an anti-smoking remedy containing Silver Acetate. Clin Exp Dermatol. 5: 305-311. | ||
| Subchronic [RfD] Comments: | The chronic oral RfD was adopted as the subchronic oral [RfD]. | ||
[ Risk Assessment Home ]
[ EPA Home |
OSWER Home | Superfund Home ]
[ Search EPA
| Search Superfund
| Whats New |
Contact Us ]
URL: http://risk.lsd.ornl.gov/epa/heast/heast_select.htm
This page was last updated on: March 1, 2000
Site maintained by: Office of Emergency and Remedial Response
Hofmann.Lee@epamail.epa.gov